PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body

Phase 1

Terminated

Conditions: Generalized Anxiety Disorder

Interventions: Drug: PD 0332334
Drug: cimetidine

First Posted Date: 2008-12-02

Last Posted Date: 2010-02-17

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00800280

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers

Phase 1

Completed

Conditions: Overweight

Interventions: Drug: Placebo
Drug: PF-04620110

First Posted Date: 2008-11-27

Last Posted Date: 2009-07-20

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT00799006

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.

Phase 4

Completed

Conditions: Urinary Bladder, Overactive

Interventions: Drug: Placebo
Drug: Fesoterodine fumarate

First Posted Date: 2008-11-26

Last Posted Date: 2011-12-14

Lead Sponsor: Pfizer

Target Recruit Count: 794

Registration Number: NCT00798434

Locations: 🇬🇧
Pfizer Investigational Site, London, United Kingdom

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)
Drug: placebo

First Posted Date: 2008-11-26

Last Posted Date: 2011-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 709

Registration Number: NCT00798707

Locations: 🇯🇵
Pfizer Investigational Site, Saitama, Japan

Rollover Protocol for Prior SU011248 Protocols

Not Applicable

Completed

Conditions: Solid Tumors

Interventions: Drug: Sunitinib

First Posted Date: 2008-11-26

Last Posted Date: 2013-01-21

Lead Sponsor: Pfizer

Target Recruit Count: 314

Registration Number: NCT00798889

Locations: 🇬🇧
Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

Phase 2

Terminated

Conditions: Meningitis, Meningococcal

Interventions: Biological: meningococcal B rLP2086 vaccine
Biological: Routine age appropriate childhood vaccines

First Posted Date: 2008-11-26

Last Posted Date: 2014-11-26

Lead Sponsor: Pfizer

Target Recruit Count: 46

Registration Number: NCT00798304

Locations: 🇪🇸
Hospital Virgen del Camino, Pamplona, Navarra, Spain
🇪🇸
Hospital Clinico Universitario de Santiago, Santiado de Compostela, La Coruña, Spain
🇪🇸
Hospital Universitario de Mostóles, Mostóles, Madrid, Spain

and more 4 locations

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

Phase 2

Completed

Conditions: Pneumonia, Bacterial

Interventions: Drug: Sulopenem and PF-03709270
Drug: Ceftriaxone and amoxicillin/clavulanate

First Posted Date: 2008-11-25

Last Posted Date: 2016-03-10

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT00797108

Locations: 🇨🇦
Hamilton Health Sciences- McMaster Site, Hamilton, Ontario, Canada
🇵🇱
Oddzial Chorob Wewnetrznych i Gastroenterologii, Bialystok, Poland
🇰🇷
Asan Medical Center, Division of Infectious Diseases, Seoul, Korea, Republic of

and more 18 locations

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04629991 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-04629991

First Posted Date: 2008-11-25

Last Posted Date: 2009-05-05

Lead Sponsor: Pfizer

Target Recruit Count: 27

Registration Number: NCT00797342

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

Phase 3

Terminated

Conditions: Pulmonary Hypertension
Pulmonary Arterial Hypertension

Interventions: Drug: Sitaxsentan
Drug: Sitaxsentan and Sildenafil

First Posted Date: 2008-11-24

Last Posted Date: 2018-10-25

Lead Sponsor: Pfizer

Target Recruit Count: 3

Registration Number: NCT00796510

Locations: 🇺🇦
Pfizer Investigational Site, Kyiv, Ukraine

Maintenance of Efficacy.

Phase 3

Withdrawn

Conditions: Fibromyalgia

Interventions: Drug: Placebo
Drug: Esreboxetine

First Posted Date: 2008-11-24

Last Posted Date: 2018-11-29

Lead Sponsor: Pfizer

Registration Number: NCT00796601

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy